= 43) (AUC, 0.94 95% CI: 0.86, 1.00). Conclusion The DMPI and midbrain area performed well for differentiating PSP from other neurodegenerative parkinsonisms. Clinical trial registration nos. NCT03068468, NCT01110720, NCT01049399, NCT01804452 © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license.
Quattrone et al. (Mon,) studied this question.